Standard

A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. / Smits, B. M.; Lelieveld, P. H. C.; Ververs, F. A. et al.

In: Clinical immunology (Orlando, Fla.), Vol. 212, 108248, 03.2020.

Research output: Contribution to journal › Letter › Academic › peer-review

Harvard

Smits, BM, Lelieveld, PHC, Ververs, FA, Turkenburg, M, de Koning, C, van Dijk, M, Leavis, HL, Boelens, JJ, Lindemans, CA, Bloem, AC, van de Corput, L, van Montfrans, J, Nierkens, S, van Gijn, ME, Geerke, DP, Waterham, HR, Koenderman, L & Boes, M 2020, 'A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease', Clinical immunology (Orlando, Fla.), vol. 212, 108248. https://doi.org/10.1016/j.clim.2019.108248

APA

Smits, B. M., Lelieveld, P. H. C., Ververs, F. A., Turkenburg, M., de Koning, C., van Dijk, M., Leavis, H. L., Boelens, J. J., Lindemans, C. A., Bloem, A. C., van de Corput, L., van Montfrans, J., Nierkens, S., van Gijn, M. E., Geerke, D. P., Waterham, H. R., Koenderman, L., & Boes, M. (2020). A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. Clinical immunology (Orlando, Fla.), 212, [108248]. https://doi.org/10.1016/j.clim.2019.108248

Vancouver

Smits BM, Lelieveld PHC, Ververs FA, Turkenburg M, de Koning C, van Dijk M et al. A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. Clinical immunology (Orlando, Fla.). 2020 Mar;212:108248. doi: 10.1016/j.clim.2019.108248

Author

Smits, B. M. ; Lelieveld, P. H. C. ; Ververs, F. A. et al. / A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. In: Clinical immunology (Orlando, Fla.). 2020 ; Vol. 212.

BibTeX

@article{f81698459c854968ae8dd83ad93d549a,
title = "A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease",
author = "Smits, {B. M.} and Lelieveld, {P. H. C.} and Ververs, {F. A.} and M. Turkenburg and {de Koning}, C. and {van Dijk}, M. and Leavis, {H. L.} and Boelens, {J. J.} and Lindemans, {C. A.} and Bloem, {A. C.} and {van de Corput}, L. and {van Montfrans}, J. and S. Nierkens and {van Gijn}, {M. E.} and Geerke, {D. P.} and Waterham, {H. R.} and L. Koenderman and M. Boes",
note = "Funding Information: We thank Ninke Nieuwenhuis and Willemien Zuilhof for discussions on and reviewing of previous studies on RAC2-GAP interactions. We also would like to thank our patients for providing us with the information and samples needed to perform this study. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = mar,
doi = "10.1016/j.clim.2019.108248",
language = "English",
volume = "212",
journal = "Clinical immunology (Orlando, Fla.)",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

RIS

TY - JOUR

T1 - A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease

AU - Smits, B. M.

AU - Lelieveld, P. H. C.

AU - Ververs, F. A.

AU - Turkenburg, M.

AU - de Koning, C.

AU - van Dijk, M.

AU - Leavis, H. L.

AU - Boelens, J. J.

AU - Lindemans, C. A.

AU - Bloem, A. C.

AU - van de Corput, L.

AU - van Montfrans, J.

AU - Nierkens, S.

AU - van Gijn, M. E.

AU - Geerke, D. P.

AU - Waterham, H. R.

AU - Koenderman, L.

AU - Boes, M.

N1 - Funding Information: We thank Ninke Nieuwenhuis and Willemien Zuilhof for discussions on and reviewing of previous studies on RAC2-GAP interactions. We also would like to thank our patients for providing us with the information and samples needed to perform this study. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85078275548&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2019.108248

DO - 10.1016/j.clim.2019.108248

M3 - Letter

C2 - 31382036

VL - 212

JO - Clinical immunology (Orlando, Fla.)

JF - Clinical immunology (Orlando, Fla.)

SN - 1521-6616

M1 - 108248

ER -

ID: 11242101